These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 17565236)

  • 1. Endogenous thrombin potential for predicting risk of venous thromboembolism in carriers of factor V Leiden.
    Lincz LF; Lonergan A; Scorgie FE; Rowlings P; Gibson R; Lawrie A; Seldon M
    Pathophysiol Haemost Thromb; 2006; 35(6):435-9. PubMed ID: 17565236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
    Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
    Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
    Gessoni G; Valverde S
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden.
    Eichinger S; Weltermann A; Philipp K; Hafner E; Kaider A; Kittl EM; Brenner B; Mannhalter C; Lechner K; Kyrle PA
    Thromb Haemost; 1999 Oct; 82(4):1232-6. PubMed ID: 10544904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombin generation and D-dimer concentrations in a patient cohort investigated for venous thromboembolism. Relations to venous thrombosis, factor V Leiden and prothrombin G20210A. The LIST study.
    Chaireti R; Jennersjö C; Lindahl TL
    Thromb Res; 2009 Jun; 124(2):178-84. PubMed ID: 19232683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis.
    de Visser MC; Guasch JF; Kamphuisen PW; Vos HL; Rosendaal FR; Bertina RM
    Thromb Haemost; 2000 Apr; 83(4):577-82. PubMed ID: 10780320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor V Leiden (Arg506Gln), a confounding genetic risk factor but not mandatory for the occurrence of venous thromboembolism in homozygotes and obligate heterozygotes for cystathionine beta-synthase deficiency.
    Yap S; O'Donnell KA; O'Neill C; Mayne PD; Thornton P; Naughten E
    Thromb Haemost; 1999 Apr; 81(4):502-5. PubMed ID: 10235428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin generation in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. A pilot study.
    Couturaud F; Duchemin J; Leroyer C; Delahousse B; Abgrall JF; Mottier D;
    Thromb Haemost; 2008 Jan; 99(1):223-8. PubMed ID: 18217158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venous thrombotic risk in family members of unselected individuals with factor V Leiden.
    Lensen RP; Bertina RM; de Ronde H; Vandenbroucke JP; Rosendaal FR
    Thromb Haemost; 2000 Jun; 83(6):817-21. PubMed ID: 10896231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of dalteparin (Fragmin) on thrombin generation in pregnant women with venous thromboembolism: significance of the factor V Leiden mutation.
    Schambeck CM; Eberl E; Geisen U; Grossmann R; Keller F
    Thromb Haemost; 2001 May; 85(5):782-6. PubMed ID: 11372668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
    Curvers J; Thomassen MC; Rimmer J; Hamulyak K; van der Meer J; Tans G; Preston FE; Rosing J
    Thromb Haemost; 2002 Jul; 88(1):5-11. PubMed ID: 12152677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism.
    Libourel EJ; Bank I; Meinardi JR; Baljé -Volkers CP; Hamulyak K; Middeldorp S; Koopman MM; van Pampus EC; Prins MH; Büller HR; van der Meer J
    Haematologica; 2002 Oct; 87(10):1068-73. PubMed ID: 12368162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variable plasma levels of Factor V Leiden correlate with circulating platelet microparticles in carriers of Factor V Leiden.
    Lincz LF; Scorgie FE; Enjeti A; Seldon M
    Thromb Res; 2012 Feb; 129(2):192-6. PubMed ID: 21798575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The procoagulant effects of factor V Leiden may be balanced against decreased levels of factor V and do not reflect in vivo thrombin formation in newborns.
    Hyytiäinen S; Wartiovaara-Kautto U; Ulander VM; Kaaja R; Heikinheimo M; Petäjä J
    Thromb Haemost; 2006 Mar; 95(3):434-40. PubMed ID: 16525570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus.
    Dizon-Townson D; Miller C; Sibai B; Spong CY; Thom E; Wendel G; Wenstrom K; Samuels P; Cotroneo MA; Moawad A; Sorokin Y; Meis P; Miodovnik M; O'Sullivan MJ; Conway D; Wapner RJ; Gabbe SG;
    Obstet Gynecol; 2005 Sep; 106(3):517-24. PubMed ID: 16135581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombin generation profile in non-thrombotic factor V Leiden carriers.
    Billoir P; Duflot T; Fresel M; Chrétien MH; Barbay V; Le Cam Duchez V
    J Thromb Thrombolysis; 2019 Apr; 47(3):473-477. PubMed ID: 30701464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombin generation and activated protein C resistance in the absence of factor V Leiden correlates with the risk of recurrent venous thromboembolism in women aged 18-65 years.
    Sonnevi K; Tchaikovski SN; Holmström M; Rosing J; Bremme K; Lärfars G
    Thromb Haemost; 2011 Nov; 106(5):901-7. PubMed ID: 21947267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms.
    Miñano A; Ordóñez A; España F; González-Porras JR; Lecumberri R; Fontcuberta J; Llamas P; Marín F; Estellés A; Alberca I; Vicente V; Corral J
    Haematologica; 2008 May; 93(5):729-34. PubMed ID: 18387978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor V Leiden in patients with venous thrombosis in Slovak population.
    Simkova M; Batorova A; Dostalova K; Pozgayova S; Simko F; Kovacs L
    Gen Physiol Biophys; 2004 Dec; 23(4):435-42. PubMed ID: 15815078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are patients with thrombophilia and previous venous thromboembolism at higher risk to arterial thrombosis?
    Linnemann B; Schindewolf M; Zgouras D; Erbe M; Jarosch-Preusche M; Lindhoff-Last E
    Thromb Res; 2008; 121(6):743-50. PubMed ID: 17804043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.